Galectin Therapeutics jumps on upbeat early-stage study data on cancer drug

Galectin Therapeutics

09/07/2021 14:16

** Shares of pharmaceutical company  GALT.O  rise 51.5%
pre-market to a near two-month high of $4.21
    ** Co announces positive results from early-stage trial of
its drug Belapectin for patients suffering from metastatic
melanoma, a form of skin cancer, and head and neck cancer
    ** The top-line clinical data was from an
investigator-initiated Phase 1b clinical trial of Belapectin in
combination with Keytruda, a prescription medicine used to treat
cancer
    ** Belapectin and Keytruda combination immunotherapy in
patients showed a cancer control rate of 56% in melanoma and of
40% in head and neck cancer  urn:newsml:reuters.com:*:nGNX2TVtyC
    ** No toxicities deemed related, probably related, or
possibly related to Belapectin were reported
    ** The combination of Belapectin and Keytruda was well
tolerated and appeared safe


 (Reporting by Shashank Nayar in Bengaluru)
 ((Shashank.Nayar@thomsonreuters.com; within U.S. +1 646 223
8780; outside U.S. +91 80 6182 2256;))